文献速递主动脉疾病

Anaconda支架系统治疗肾下腹主动脉瘤19年两中心结果

Nineteen-year outcomes with the Anaconda stent graft system from two tertiary centers.
PubMed 文献 · J Vasc Surg · 2021-03-02

该研究回顾性分析了两家高容量中心19年间连续260例接受Anaconda支架治疗的肾下腹主动脉瘤患者,技术成功率98.5%,围手术期死亡2例(0.8%)。

要点

  • Anaconda支架治疗肾下AAA技术成功率98.5%,围手术期死亡0.8%。
  • 随访中无晚期AAA破裂或AAA相关死亡,远期生存1年94.8%、5年75.2%。
  • 晚期肢体闭塞是再干预主因,术中髂动脉亲吻球囊可显著降低11年肢体血栓率。

核心结论

  • Anaconda支架在19年真实世界研究中显示出有效且持久的AAA治疗效果,研究人群中无晚期AAA破裂或AAA相关死亡。
  • 晚期肢体闭塞是再干预的主要原因,术中亲吻球囊与非顺应性球囊血管成形术与随时间显著降低的髂动脉血栓率相关。

研究设计与样本

  • 回顾性分析两家高容量中心2000至2019年间连续260例接受Anaconda支架治疗的肾下腹主动脉瘤患者,随访至少1年。
  • 长期结果采用Kaplan-Meier法评估,平均随访54±38个月(汇总随访指数=0.86)。

主要发现

  • 技术成功率为98.5%(256/260),围手术期死亡2例(0.8%),主要并发症4例(1.5%)。
  • 晚期生存估计1年94.8%、5年75.2%、10年50.5%、13年43.3%,无晚期AAA破裂或AAA相关死亡。
  • 免于晚期转换开放手术1年99.2%、5年96.9%、10年94.0%、13年94.0%。
  • 免于晚期肢体血栓1年96.8%、5/10/13年均为91.0%;免于晚期再干预1年95.6%、5年87.0%、10/13年均为77.4%。

临床怎么用

  • Anaconda支架可用于肾下AAA的腔内治疗,远期结果支持其持久性,但需关注晚期肢体闭塞风险。
  • 术中考虑使用髂动脉亲吻球囊与非顺应性球囊血管成形术可能降低远期肢体血栓发生率。

局限性

  • 回顾性研究设计,数据来自两家高容量中心,可能存在选择偏倚。
  • 平均随访54±38个月,部分患者随访时间不足以覆盖全部19年观察期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Anaconda stent graft device presents peculiar and unique features in its design and deployment sequence, available on the market for many years with minor modifications, among different generations. The aim of this study was to assess the long-term, real-life, outcomes obtained in two high-volume centers with this endograft for infrarenal aortic aneurysms treatment over a period of 19 years. METHODS: All patients treated with the investigated device between 2000 and 2019, with at least 1 year of follow-up, were entered into a prospective database and data were reviewed retrospectively. The long-term results were assessed according to the Kaplan-Meier method. Primary outcomes were overall survival, freedom from AAA rupture, and freedom from AAA-related death. Secondary outcomes were freedom from late reintervention, freedom from late conversion to open repair, freedom from late limb occlusion, and freedom from late EVAR failure. RESULTS: A total of 260 consecutive patients were treated during the study period. Technical success was achieved in 98.5% (256/260) of the cases. Two perioperative deaths (0.8%) and four major complications (1.5%) were recorded. At a mean follow-up of 54 ± 38 months (summary follow-up index = 0.86), the late survival estimate was 94.8% at 1 year, 75.2% at 5 years, 50.5% at 10 years, and 43.3% at 13 years, with no case of late AAA rupture or late AAA-related death. Late freedom from conversion was 99.2% at 1 year, 96.9% at 5 years, 94.0% at 10 years, and 94.0% at 13 years. Freedom from late limb thrombosis was 96.8% at 1 year and 91.0% at 5, 10, and 13 years. Estimates of freedom from late reintervention was 95.6% at 1 year, 87.0% at 5 years, 77.4% at 10 years, and 77.4% at 13 years. Estimates of limb thrombosis at 11 years were significantly different in patients receiving or not intraoperative iliac kissing balloon maneuver with noncompliant angioplasty catheters (98.0% vs 88.4%; P = .029). CONCLUSIONS: The Anaconda stent graft demonstrated effective and durable outcomes for AAA treatment over a 19-year period, with no case of late AAA rupture or AAA related death in the studied population. Late limb occlusion was the leading cause of reintervention; however, a positive prevention strategy was found in intraoperative kissing balloon, which was associated with significant reduced rate of iliac thrombosis over time.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Isernia G, Simonte G, Michelagnoli S, et al. Nineteen-year outcomes with the Anaconda stent graft system from two tertiary centers. J Vasc Surg. 2021. PMID: 33348006. doi:10.1016/j.jvs.2020.12.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。